The tweet was deleted by the author.
But we saved everything 🙂.
Guy LeBas highlights a significant move in the S&P Biotech index, noting a negative shift of two standard deviations. According to LeBas, there have been few days with worse single-day underperformance, with only one worse day in June 2026, two in 2023, two in 2022, and no comparably poor showings since 2017.
View post on X Loading...
LeBas has previously commented on fixed income and equity flows at key market moments. In September, he reported increased buying of fixed income and selling of equities. He has also observed that U.S. Treasury auctions continued without event during recent issuances.